Related Experiment Video
Updated: Jul 16, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Neoadjuvant radiochemotherapy for rectal cancer
1Department of Radiotherapy, Athens Medical Center, Athens, Greece. lvini@iatriko.gr
Digestive Diseases (Basel, Switzerland)
|March 27, 2007
Summary
Total mesorectal excision has advanced rectal cancer care. Preoperative radiotherapy, with or without 5-FU chemotherapy, significantly reduces local recurrence and improves survival for rectal cancer patients.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Total mesorectal excision (TME) has significantly improved rectal cancer management.
- The efficacy of radiotherapy in enhancing local control and survival is a key area of research.
Purpose of the Study:
- To review the role and effectiveness of preoperative radiotherapy in rectal cancer treatment.
- To evaluate the impact of chemotherapy on radiotherapy response and patient outcomes.
Main Methods:
- Analysis of randomized trials comparing different preoperative radiotherapy regimens (short-course vs. conventionally fractionated).
- Review of studies investigating the addition of 5-FU-based chemotherapy to preoperative radiotherapy.
- Comparison of preoperative versus postoperative radiotherapy regarding local control and toxicity.
Main Results:
- Preoperative radiotherapy, both short and conventional regimens, significantly reduces local recurrence rates.
- Some trials demonstrated survival improvements with preoperative radiotherapy.
- Preoperative radiotherapy shows better local control and lower toxicity compared to postoperative therapy.
- 5-FU-based chemotherapy enhances tumor response to radiotherapy, supporting preoperative chemoradiotherapy.
Conclusions:
- Preoperative radiotherapy is a highly effective treatment for improving local control in rectal cancer.
- Preoperative chemoradiotherapy is increasingly utilized for stage II and III rectal cancer due to enhanced efficacy.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.